InvestBio’s Biotech Investments: We Invest in Tomorrow’s Biotech Companies Today

InvestBio has participated in the following biotech companies:

Alteon Inc.
Alteon Inc. is a product-based biopharmaceutical company engaged in the development of small-molecule drugs to reverse or slow down diseases of aging and complications of diabetes. The Company's lead compound, Alagebrium Chloride (formerly ALT-711), is in clinical development, and several others are in earlier development stages. These pharmaceutical candidates were developed as a result of Alteon's research on the Advanced Glycation End-Products (A.G.E.) pathway (a pathological process and inevitable consequence of aging that causes or contributes to many medical disorders, including cardiovascular, kidney, and eye diseases).

Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics, Inc.

Kinexis, Inc.
Kinexis, Inc. is a life science R&D company targeting pathology-linked oligomeric conformations of amyloid proteins involved in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and prion (Creutzfeld-Jakob) disease. Its strategy is to leverage a revenue-generating product stream through sponsored research and by forming relationships with major pharmaceutical and biotechnology companies. Kinexis' proprietary technology allows generation of antibody responses specific for cytotoxic conformations of multiple amyloid proteins. Kinexis is commercializing its technology through development of biopharmaceutical products based on active immunization, passive immunotherapy, and small molecule screening strategies. Using its proprietary immunization technology, Kinexis has already identified product opportunities for Alzheimer's disease where active immunization and passive immunotherapy strategies have yielded dramatic pharmacological effects in animal models.

Trellis Bioscience, Inc.
Trellis Bioscience, Inc. is a venture backed biopharmaceutical company whose breakthrough technology for the discovery and optimization of peptide therapeutics enables a qualitatively new approach to inhibiting protein-protein interactions. Such interactions are central to most biological processes - from intracellular and extra cellular communication, to programmed cell death - and represent a large and important class of targets for human therapeutics. Despite the plethora of such targets that have been identified over the past decade, most drug discovery technologies have been unable to identify drug-like molecules that interfere with these interactions. Trellis has combined its proprietary multiplex detection technology with in-licensed technology from a prominent university laboratory, enabling the rapid generation of small, highly stable peptide scaffolds that potently and selectively block these important targets. Using this highly efficient platform the company will develop a pipeline of clinical candidates, with an initial focus in the discovery and development of cancer therapeutics.

For biotech investment questions please contact *DPEC Partners.

* InvestBio does not offer any securities. InvestBio's biotech investment products and services can only be obtained through DPEC Capital, Inc.

Market Growth from 2004 to 2010: HEM hematology; ONCO, oncology; D&E, Diabetes and endocrinology; ID*, infectious diseases including HIV; AIID, Arthritis inflammation and immune disorders; CNS, central neural system; GD, genetic disorders; WH, woman's health. Others**, respiratory plus cardiovascular;
Source: Datamonitor and company-reported information.
Nature Publishing Group
Nature Biotechnology